MASTER DAPT is the largest multi-center randomized controlled study on the use of short duration of dual antiplatelet therapy (DAPT) in high bleeding risk patients following stenting procedures with Ultimaster™ Family DES.
MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe. The study is managed by global CROs and data management groups (CERC, Paris, France, Cardialysis, Rotterdam, The Netherlands, CV quest. Co. Ltd., Tokyo, Japan and CTU, Bern, Switzerland).
